{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:51:45Z","timestamp":1781607105356,"version":"3.54.5"},"reference-count":35,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,2,15]]},"abstract":"<jats:p>Moxifloxacin is an attractive drug for the treatment of isoniazid-resistant rifampicin-susceptible tuberculosis (TB) or drug-susceptible TB complicated by isoniazid intolerance. However, co-administration with rifampicin decreases moxifloxacin exposure.<\/jats:p>","DOI":"10.1128\/aac.01829-21","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T20:42:27Z","timestamp":1637613747000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":10,"title":["Clinical Relevance of Rifampicin\u2010Moxifloxacin Interaction in Isoniazid-Resistant\/Intolerant Tuberculosis Patients"],"prefix":"10.1128","volume":"66","author":[{"given":"Vanessa B.","family":"Vogensen","sequence":"first","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu S.","family":"Bolhuis","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke G. G.","family":"Sturkenboom","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjip S.","family":"van der Werf","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiel C. M.","family":"de Lange","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, the Netherlands"},{"name":"University of Groningen, University Medical Center Groningen, TB Center Beatrixoord, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Anthony","sequence":"additional","affiliation":[{"name":"National Institute for Public Health and the Environment, TB Reference Laboratory (RIVM), Bilthoven, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"van Soolingen","sequence":"additional","affiliation":[{"name":"National Institute for Public Health and the Environment, TB Reference Laboratory (RIVM), Bilthoven, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0288","authenticated-orcid":true,"given":"Jan-Willem","family":"Alffenaar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, School of Pharmacy, University of Sydney, Sydney, NSW, Australia"},{"name":"Westmead Hospital, Westmead, NSW, Australia"},{"name":"Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7705-7927","authenticated-orcid":true,"given":"Huib A. M.","family":"Kerstjens","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5638-9260","authenticated-orcid":true,"given":"Onno W.","family":"Akkerman","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, the Netherlands"},{"name":"University of Groningen, University Medical Center Groningen, TB Center Beatrixoord, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"Global tuberculosis report 2020.","author":"World Health Organization (WHO)","year":"2020","unstructured":"World Health Organization (WHO). 2020. Global tuberculosis report 2020. World Health Organization, Geneva, Switzerland. https:\/\/www.who.int\/publications\/i\/item\/9789240013131. Accessed 12 March 2021."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01727-2020"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003008"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30407-8"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2019.24.12.1800392"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.16.0716"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30078-X"},{"key":"e_1_3_2_10_2","unstructured":"World Health Organization (WHO). 2018. WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis. World Health Organization Geneva Switzerland. https:\/\/www.who.int\/tb\/publications\/2018\/WHO_guidelines_isoniazid_resistant_TB\/en\/. Accessed 18 March 2021."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.968"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/521894"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01621-06"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140050-00002"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01253-08"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00867-1"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00176610"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/424849"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00176610"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.2060"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.5.669"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213718"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00038-17"},{"key":"e_1_3_2_24_2","unstructured":"ClinicalTrials.gov. 2021. Rifampicin at high dose for difficult-to-treat tuberculosis (RIAlta). National Library of Medicine Bethesda MD USA. Identifier: NCT00287391. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04768231"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342090-00003"},{"key":"e_1_3_2_26_2","unstructured":"Sekaggya-Wiltshire C Nabisere R Musaazi J Aber F Otaalo B Lamorde M Denti P Aarnoutse R Dooley K Sloan DJ. 2021. PK and safety of high-dose rifampicin in TB\/HIV coinfected patients on efavirenz or dolutegravir abstr 90. Abstr Virtual Conference on Retroviruses and Opportunistic Infections. https:\/\/www.croiconference.org\/abstract\/pk-and-safety-of-high-dose-rifampicin-in-tb-hiv-coinfected-patients-on-efv-or-dtg\/."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00384-19"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0935"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03463-2020"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00373-2019"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1073"},{"key":"e_1_3_2_32_2","first-page":"979","article-title":"Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifoxacin","volume":"136","author":"Ramachandran G","year":"2012","unstructured":"Ramachandran G, Kumar AKH, Srinivasan R, Geetharani A, Sugirda P, Nandhakumar B, Nandini R, Tharani CB. 2012. Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifoxacin. Indian J Med Res 136:979\u2013984. https:\/\/pubmed.ncbi.nlm.nih.gov\/23391793\/.","journal-title":"Indian J Med Res"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2017-0144"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx004"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/34.3.135"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0000000000000389"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01829-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01829-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:26:20Z","timestamp":1645485980000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01829-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,15]]}},"alternative-id":["10.1128\/aac.01829-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.01829-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]},"assertion":[{"value":"2021-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01829-21"}}